Cytomegalovirus

Infectious Diseases of the Fetus and Newborn Infant

Volumn , Issue , 2011, Pages 706-755

  Britt, William ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875983803     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6400-8.00023-7     Document Type: Chapter

References (646)

1. Weller T.H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. N. Engl. J. Med. 1971, 285:203-214.
2. Ribbert D. Uber protozoenartige zellen in der niere eines syphilitischen neugoborenen und in der parotis von kindern. Zentralbl. Allg. Pathol. 1904, 15:945-948.
3. Jesionek A., Kiolemenoglou B. Uber einen befund von protozoenartigen gebilden in den organen eines heriditarluetischen fotus. Munch. Med. Wochenschr. 1904, 51:1905-1907.
4. Lowenstein C. Uber protozoenartigen Gebilden in de Organen von Dindern. Zentralbl. Allg. Pathol. 1907, 18:513-518.
5. Goodpasture E.W., Talbot F.B. Concerning the nature of "proteozoan-like" cells in certain lesions of infancy. Am. J. Dis. Child. 1921, 21:415-421.
6. Lipschutz B. Untersuchungen uber die atiologie der krankheiten der herpesgruppe (herpes zoster, herpes genitalis, herpes febrilis). Arch. Derm. Syph. (Berl) 1921, 136:428-482.
7. Cole R., Kuttner A.G. A filtrable virus present in the submaxillary glands of guinea pigs. J. Exp. Med. 1926, 44:855-873.
8. Smith M.G. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus disease. Proc. Soc. Exp. Biol. (NY) 1956, 92:424-430.
9. Rowe W.P., et al. Cytopathogenic agents resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc. Soc. Exp. Biol. (NY) 1956, 92:418-424.
10. Weller T.H., et al. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc. Soc. Exp. Biol. Med. 1957, 94:4-12.
11. Weller T.H., Hanshaw J.B., Scott D.E. Serologic differentiation of viruses responsible for cytomegalic inclusion disease. Virology 1960, 12:130-132.
12. Krech U., Konjajev Z., Jung M. Congenital cytomegalovirus infection in siblings from consecutive pregnancies. Helv. Paediatr. Acta. 1971, 26:355-362.
13. Gold E., Nankervis G.A. Cytomegalovirus. Viral Infections of Humans: Epidemiology and Control 1982, 167-186. Plenum Press, New York. second ed. A.S. Evans (Ed.).
14. Davison A.J., et al. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome [erratum appears in J Gen Virol 84(Pt 4):1053, 2003]. J. Gen. Virol. 2003, 84:17-28.
15. Bradley A.J., et al. Genotypic analysis of two hypervariable human cytomegalovirus genes. J. Med. Virol. 2008, 80:1615-1623.
16. Black J.B., Pellett P.E. Human herpesvirus 7. Rev. Med. Virol. 1999, 9:245-262.
17. Campadelli-Fiume G., Mirandola P., Menotti L. Human herpesvirus 6: an emerging pathogen. Emerg. Infect. Dis. 1999, 5:353-366.
18. Clark D.A. Human herpesvirus 6. Rev. Med. Virol. 2000, 10:155-173.
19. Chen D.H., et al. Three-dimensional visualization of tegument/capsid interactions in the intact human cytomegalovirus. Virology 1999, 260:10-16.
20. Trus B.L., et al. Capsid structure of simian cytomegalovirus from cryoelectron microscopy: evidence for tegument attachment sites [erratum appears in J Virol 73(5):4530, 1999]. J. Virol. 1999, 73:2181-2192.
21. Murphy E., et al. Coding capacity of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14976-14981.
22. Mocarski E.S., Tan Courcelle C. Cytomegaloviruses and their replication. Virology 2001, 2629-2673. Lippincott Williams & Wilkins, Philadelphia. fourth ed. B.N. Fields (Ed.).
23. Borst E.M., et al. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 1999, 73:8320-8329.
24. Mocarski E. Betaherpes viral genes and their function. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis 2007, 204-230. Cambridge University Press, Cambridge. A. Arvin (Ed.).
25. Varnum S.M., et al. Identification of proteins in human cytomegalovirus (HCMV) particles: The HCMV proteome [erratum appears in J Virol 78(23):13395, 2004]. J. Virol. 2004, 78:10960-10966.
26. Murphy E., Shenk T. Human cytomegalovirus genome. Human Cytomegalovirus 2008, 1-20. Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
27. Britt W. Maturation and egress. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis 2007, 311-323. Cambridge University Press, Cambridge. A. Arvin (Ed.).
28. Gibson W. Structure and function of the cytomegalovirus virion. Human Cytomegalovirus 2008, 187-204. Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
29. Bogner E., Radsak K., Stinski M.F. The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J. Virol. 1998, 72:2259-2264.
30. Scheffczik H., et al. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucl. Acids Res. 2002, 30:1695-1703.
31. Krosky P.M., et al. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 1998, 72:4721-4728.
32. Mou F., et al. Effects of lamin A/C, lamin B1, and viral US3 kinase activity on viral infectivity, virion egress, and the targeting of herpes simplex virus U(L)34-encoded protein to the inner nuclear membrane. J. Virol. 2008, 82:8094-8104.
33. Reynolds A.E., et al. Ultrastructural localization of the herpes simplex virus type 1 UL31, UL34, and US3 proteins suggests specific roles in primary envelopment and egress of nucleocapsids. J. Virol. 2002, 76:8939-8952.
34. Krosky P.M., Baek M.C., Coen D.M. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 2003, 77:905-914.
35. Hamirally S., et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 2009, 5. e1000275.
36. Bresnahan W.A., Shenk T. A subset of viral transcripts packaged within human cytomegalovirus particles. Science 2000, 288:2373-2376.
37. Hume A.J., Kalejta R.F. Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div. 2009, 4:1.
38. Kalejta R.F. Functions of human cytomegalovirus tegument proteins prior to immediate early gene expression. Curr. Top. Microbiol. Immunol. 2008, 325:101-115.
39. Hume A.J., et al. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 2008, 320:797-799.
40. Fortunato E.A., Spector D.H. p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J. Virol. 1998, 72:2033-2039.
41. Salvant B.S., Fortunato E.A., Spector D.H. Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. J. Virol. 1998, 72:3729-3741.
42. Hayashi M.L., Blankenship C., Shenk T. Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2692-2696.
43. Baldick C.J., et al. Human cytomegalovirus tegument protein pp 71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle. J. Virol. 1997, 71:4400-4408.
44. Buchkovich N.J., et al. The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nat. Rev. Microbiol. 2008, 6:266-275.
45. Alwine J.C. Modulation of host cell stress responses by human cytomegalovirus. Curr. Top. Microbiol. Immunol. 2008, 325:263-279.
46. Buchkovich N.J., et al. Human cytomegalovirus specifically controls the levels of the endoplasmic reticulum chaperone BiP/GRP78, which is required for virion assembly. J. Virol. 2008, 82:31-39.
47. Kudchodkar S.B., et al. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14182-14187.
48. Munger J., et al. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol. 2008, 26:1179-1186.
49. Moorman N.J., et al. Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex. Cell Host Microbe 2008, 3:253-262.
50. Landini M.P., LaPlaca M. Humoral immune response to human cytomegalovirus proteins: a brief review. Comp. Immunol. Microbiol. Infect. Dis. 1991, 14:97-105.
51. Zaia J.A., et al. Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients. J. Infect. Dis. 1986, 153:780-787.
52. Sylwester A.W., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
53. Hayes K., Alford C.A., Britt W.J. Antibody response to virus-encoded proteins after cytomegalovirus mononucleosis. J. Infect. Dis. 1987, 156:615-621.
54. Kern F., et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 2002, 185:1709-1716.
55. Boppana S.B., Britt W.J. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 1996, 222:293-296.
56. Chee M.S., et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol. 1990, 154:125-170.
57. Britt W.J., Boppana S. Human cytomegalovirus virion proteins. Hum. Immunol. 2004, 65:395-402.
58. Eickmann M., Glickhorn D., Radsak K. Glycoprotein trafficking in virion morphogenesis. Cytomegaloviruses: Molecular Biology and Immunology 2006, 245-264. Casiter, Norfolk, UK. M.J. Reddehase (Ed.).
59. Mach M. Antibody-mediated neutralization of infectivity. Cytomegaloviruses: Molecular Biology and Immunology 2006, 265-283. Casiter, Norfolk, UK. M.J. Reddehase (Ed.).
60. Wang D., et al. Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20037-20042.
61. Hahn G., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 2004, 78:10023-10033.
62. Ryckman B.J., Chase M.C., Johnson D.C. HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14118-14123.
63. Cui X., et al. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26:5760-5766.
64. Britt W.J., et al. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-vaccinia recombinant virus infected cells in analysis of the human neutralizing antibody response. J. Virol. 1990, 64:1079-1085.
65. Meyer H., Masuho Y., Mach M. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J. Gen. Virol. 1990, 71:2443-2450.
66. Rasmussen L., et al. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J. Infect. Dis. 1991, 164:835-842.
67. Marshall G.S., et al. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis. 1992, 165:381-384.
68. Urban M., et al. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J. Gen. Virol. 1996, 77:1537-1547.
69. Compton T. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol. 2004, 14:5-8.
70. Boehme K.W., Compton T. Virus entry and activation of innate immunity. Cytomegaloviruses: Molecular Biology and Immunology 2006, 111-130. Casiter, Norfolk, UK. M.J. Reddehase (Ed.).
71. Wang X., et al. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003, 424:456-461.
72. Wang X., et al. Integrin αvβ3 is a coreceptor for human cytomegalovirus. Nat. Med. 2005, 11:515-521.
73. Feire A.L., Koss H., Compton T. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15470-15475.
74. Soroceanu L., Akhavan A., Cobbs C.S. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008, 455:391-395.
75. Cobbs C.S., et al. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J. Neurooncol. 2007, 85:271-280.
76. Zhu H., et al. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14470-14475.
77. Zhu H., Cong J.P., Shenk T. Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of interferon-responsive RNAs. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13985-13990.
78. Browne E.P., et al. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J. Virol. 2001, 75:12319-12330.
79. Simmen K.A., et al. Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7140-7145.
80. Yu Y., Alwine J.C. Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3p-OH kinase pathway and the cellular kinase Akt. J. Virol. 2002, 76:3731-3738.
81. Sambucetti L.C., et al. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 1989, 8:4251-4258.
82. Child S., et al. Complementation of vaccinia virus lacking the double stranded RNA-binding protein gene E3L by human cytomegalovirus. J. Virol. 2002, 76:4912-4918.
83. Hakki M., Geballe A.P. Double-stranded RNA binding by human cytomegalovirus pTRS1. J. Virol. 2005, 79:7311-7318.
84. Zimmerman A., Hengel H. Cytomegalovirus interference with interferons. Cytomegaloviruses: Molecular Biology and Immunology 2006, 321-339. Casiter, Norfolk, UK. M.J. Reddehase (Ed.).
85. Ogawa-Goto K., et al. Microtubule network facilitates nuclear targeting of human cytomegalovirus capsid. J. Virol. 2003, 77:8541-8547.
86. Radtke K., Dohner K., Sodeik B. Viral interactions with the cytoskeleton: a hitchhiker's guide to the cell. Cell. Microbiol. 2006, 8:387-400.
87. Wolfstein A., et al. The inner tegument promotes herpes simplex virus capsid motility along microtubules in vitro. Traffic 2006, 7:227-237.
88. Stinski M.F., Shenk T. Functional roles of the human cytomegalovirus essential IE86 protein. Human Cytomegalovirus 2008, 133-152. Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
89. McCormick A.L. Control of apoptosis by human cytomegalovirus. Human Cytomegalovirus 2008, 281-294. Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
90. Cullen B.R. Viral and cellular messenger RNA targets of viral microRNAs. Nature 2009, 457:421-425.
91. Gottwein E., Cullen B.R. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 2008, 3:375-387.
92. Grey F., Nelson J. Identification and function of human cytomegalovirus microRNAs. J. Clin. Virol. 2008, 41:186-191.
93. Grey F., et al. A human cytomegalovirus-encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS Pathog. 2007, 3:e163.
94. Nelson J.A. Small RNAs and large DNA viruses. N. Engl. J. Med. 2007, 357:2630-2632.
95. Grey F., et al. Identification and characterization of human cytomegalovirus-encoded microRNAs. J. Virol. 2005, 79:12095-12099.
96. Murphy E., et al. Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5453-5458.
97. Pari G. Nuts and bolts of human cytomegalovirus lytic DNA replication. Human Cytomegalovirus 2008, 153-166. Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
98. Newcomb W.W., et al. In vitro assembly of the herpes simplex virus procapsid: formation of small procapsids at reduced scaffolding protein concentration. J. Struct. Biol. 2001, 133:23-31.
99. Heymann J.B., et al. Dynamics of herpes simplex virus capsid maturation visualized by time-lapse cryo-electron microscopy. Nat. Struct. Biol. 2003, 10:334-341.
100. Sanchez V., et al. Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly. J. Virol. 2000, 74:975-986.
101. Homman-Loudiyi M., et al. Envelopment of human cytomegalovirus occurs by budding into Golgi-derived vacuole compartments positive for gB, Rab 3, trans-Golgi network 46, and mannosidase II [erratum appears in J Virol 77(14):8179, 2003]. J. Virol. 2003, 77:3191-3203.
102. Das S., Vasanji A., Pellett P.E. Three-dimensional structure of the human cytomegalovirus cytoplasmic virion assembly complex includes a reoriented secretory apparatus. J. Virol. 2007, 81:11861-11869.
103. Taylor-Wiedeman J., Sissons P., Sinclair J. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J. Virol. 1994, 68:1597-1604.
104. Kondo K., Xu J., Mocarski E.S. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11137-11142.
105. Soderberg-Naucler C., Fish K.N., Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997, 91:119-126.
106. Soderberg-Naucler C., Fish K.N., Nelson J.A. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J. Clin. Invest. 1997, 100:3154-3163.
107. Reeves M., Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Human Cytomegalovirus 2008, 297-313. Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
108. Bolovan-Fritts C.A., Mocarski E.S., Wiedeman J.A. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999, 93:394-398.
109. Soderberg-Naucler C., et al. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J. Virol. 2001, 75:7543-7554.
110. Gnann J.W., et al. Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am. J. Pathol. 1988, 132:239-248.
111. Hummel M., et al. Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J. Virol. 2001, 75:4814-4822.
112. Hummel M., Abecassis M.M. A model for reactivation of CMV from latency. J. Clin. Virol. 2002, 25(Suppl. 2):S123-S136.
113. Roback J.D., et al. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 2001, 41:1249-1257.
114. Sinzger C., et al. Cell types infected in human cytomegalovirus placentitis identified by immunohistochemical double staining. Virchows Arch A. Pathol. Anat. Histopathol. 1993, 423:249-256.
115. Sinzger C., et al. Immunohistochemical detection of viral antigens in smooth muscle, stromal, and epithelial cells from acute human cytomegalovirus gastritis. J. Infect. Dis. 1993, 167:1427-1432.
116. Sinzger C., Digel M., Jahn G. Cytomegalovirus cell tropism. Human Cytomegalovirus 2008, 63-84. Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
117. Ryckman B.J., et al. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J. Virol. 2006, 80:710-722.
118. Colugnati F.A., et al. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect. Dis. 2007, 7:71.
119. Staras S.A., et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin. Infect. Dis. 2006, 43:1143-1151.
120. Wilms I.R., Best A.M., Adler S.P. Cytomegalovirus infections among African-Americans. BMC Infect. Dis. 2008, 8:107.
121. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 2007, 17:253-276.
122. Stagno S., et al. Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outcome. JAMA 1986, 256:1904-1908.
123. Jordan M.C., et al. Association of cervical cytomegaloviruses with venereal disease. N. Engl. J. Med. 1973, 288:932-934.
124. Coonrod D., et al. Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. J. Infect. Dis. 1998, 177:1188-1193.
125. Drew W.L., et al. Prevalence of cytomegalovirus infection in homosexual men. J. Infect. Dis. 1981, 143:188-192.
126. Chandler S.H., et al. The epidemiology of cytomegaloviral infection in women attending a sexually transmitted disease clinic. J. Infect. Dis. 1985, 152:597-605.
127. Ross S.A., et al. Association between genital tract cytomegalovirus infection and bacterial vaginosis. J. Infect. Dis. 2005, 192:1727-1730.
128. Hayes D., et al. Cytomegalovirus in human milk. N. Engl. J. Med. 1972, 287:177.
129. Dworsky M., et al. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics 1983, 72:295-299.
130. Hamprecht K., et al. Detection of cytomegaloviral DNA in human milk cells and cell free milk whey by nested PCR. J. Virol. Method. 1998, 70:167-176.
131. Hamprecht K., et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001, 357:513-518.
132. Pass R.F., et al. Cytomegalovirus infection in a day care center. N. Engl. J. Med. 1982, 307:477-479.
133. Adler S.P. The molecular epidemiology of cytomegalovirus transmission among children attending a day care center. J. Infect. Dis. 1985, 152:760-768.
134. Murph J.R., et al. Cytomegalovirus transmission in a Midwest day care center: possible relationship to child care practices. J. Pediatr. 1986, 109:35-39.
135. Murph J.R., Bale J.F. The natural history of acquired cytomegalovirus infection among children in group day care. Am. J. Dis. Child. 1988, 142:843-846.
136. Hutto S.C., et al. Epidemiology of cytomegalovirus infections in young children: day care vs home care. Pediatr. Infect. Dis. 1985, 4:149-152.
137. Pass R.F., et al. Young children as a probable source of maternal and congenital cytomegalovirus infection. N. Engl. J. Med. 1987, 316:1366-1370.
138. Stagno S., Cloud G.A. Working parents: the impact of day care and breast-feeding on cytomegalovirus infections in offspring. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:2384-2389.
139. Hutto C., et al. Isolation of cytomegalovirus from toys and hands in a day care center. J. Infect. Dis. 1986, 154:527-530.
140. Faix R.G. Survival of cytomegalovirus on environmental surfaces. J. Pediatr. 1985, 106:649-652.
141. Dworsky M., Lakeman A., Stagno S. Cytomegalovirus transmission within a family. Pediatr. Infect. Dis. 1984, 3:236-238.
142. Murph J.R., et al. Epidemiology of congenital cytomegalovirus infection: maternal risk factors and molecular analysis of cytomegalovirus strains. Am. J. Epidemiol. 1998, 147:940-947.
143. Murph J.R., et al. The occupational risk of cytomegalovirus infection among day-care providers. JAMA 1991, 265:603-608.
144. Spector S.A., Spector D.H. Molecular epidemiology of cytomegalovirus infections in premature twin infants and their mother. Pediatr. Infect. Dis. J. 1982, 1:405-409.
145. Yeager A.S. Transmission of cytomegalovirus to mothers by infected infants: another reason to prevent transfusion-acquired infections. Pediatr. Infect. Dis. 1983, 2:295.
146. Dworsky M., et al. Occupational risk for primary cytomegalovirus infection among pediatric health care workers. N. Engl. J. Med. 1983, 309:950-953.
147. Taber L.H., Frank A.L., Yow M.D., Bagley A. Acquisition of cytomegaloviral infections in families with young children: a serological study. J Infect Dis 1985, 151:948-952.
148. Adler S.P. Cytomegalovirus and child day care: evidence for an increased infection rate among day-care workers. N. Engl. J. Med. 1989, 321:1290-1296.
149. Adler S.P. Molecular epidemiology of cytomegalovirus: viral transmission among children attending a day care center, their parents, and caretakers. J. Pediatr. 1988, 112:366-372.
150. Adler S.P., et al. Molecular epidemiology of cytomegalovirus in a nursery: lack of evidence for nosocomial transmission. J. Pediatr. 1986, 108:117-123.
151. Pass R.F., et al. Increased rate of cytomegalovirus infection among parents of children attending day care centers. N. Engl. J. Med. 1986, 314:1414-1418.
152. Marshall B.C., Adler S.P. The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care. Am. J. Obstet. Gynecol. 2009, 200(163):e1-e5.
153. Schopfer K., Lauber E., Krech U. Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy. Arch. Dis. Child. 1978, 53:536-539.
154. Stagno S., et al. Congenital cytomegalovirus infection: occurrence in an immune population. N. Engl. J. Med. 1977, 296:1254-1258.
155. Embil J.A., Ozere R.J., Haldane E.V. Congenital cytomegalovirus infection in two siblings from consecutive pregnancies. J. Pediatr. 1970, 77:417-421.
156. Yamamoto A.Y., et al. Congenital cytomegalovirus infection in preterm and full-term newborn infants from a population with a high seroprevalence rate. Pediatr. Infect. Dis. J. 2001, 20:188-192.
157. Dar L., et al. Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr. Infect. Dis. J. 2008, 27:841-843.
158. Mussi-Pinhata M.M., et al. Birth prevalence and natural history of congenital cytomegalovirus (CMV) infection in highly seroimmune population. Clin. Infect. Dis. 2009, 49:522-528.
159. Stagno S., et al. Maternal cytomegalovirus infection and perinatal transmission. Clin. Obstet. Gynecol. 1982, 25:563-576.
160. Boppana S.B., et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med. 2001, 344:1366-1371.
161. Gehrz R.C., et al. Cytomegalovirus specific humoral and cellular immune responses in human pregnancy. J. Infect. Dis. 1981, 143:391-395.
162. Lilleri D., et al. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J. Infect. Dis. 2007, 195:1062-1070.
163. Boppana S.B., Britt W.J. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J. Infect. Dis. 1995, 171:1115-1121.
164. Boppana S.B., Miller J., Britt W.J. Transplacentally acquired antiviral antibodies and outcome in congenital human cytomegalovirus infection. Viral Immunol. 1996, 9:211-218.
165. Pass R.F. Transmission of viruses through human milk. Role of Human Milk in Infant Nutrition and Health 1986, 205-224. Charles C Thomas, Springfield, IL. R.R. Howell, F.H. Morriss, L.K. Pickering (Eds.).
166. Handsfield H.H., et al. Cytomegalovirus infection in sex partners: evidence for sexual transmission. J. Infect. Dis. 1985, 151:344-348.
167. Staras S.A., et al. Influence of sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994. Sex. Transm. Dis. 2008, 35:472-479.
168. Kreel I., et al. A syndrome following total body perfusion. Surg. Gynecol. Obstet. 1960, 111:317-321.
169. Seaman A.J., Starr A. Febrile post-cariotomy lymphocytic splenomegaly: a new entity. Ann. Surg. 1962, 156:956-960.
170. Armstrong J.A., et al. Cytomegalovirus infection in children undergoing open heart surgery. Yale J. Biol. Med. 1976, 49:83-91.
171. Prince A.M., et al. A serologic study of cytomegalovirus infections associated with blood transfusions. N. Engl. J. Med. 1971, 284:1125-1131.
172. Stevens D.P., et al. Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery. JAMA 1970, 211:1341-1344.
173. McCracken G.J., et al. Congenital cytomegalic inclusion disease: a longitudinal study of 20 patients. Am. J. Dis. Child. 1969, 117:522-539.
174. Kumar A., et al. Acquisition of cytomegalovirus infection in infants following exchange transfusion: a prospective study. Transfusion 1980, 20:327-331.
175. Yeager A.S., et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr. 1981, 98:281-287.
176. Meyers J.D., Flournoy N., Thomas E.D. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev. Infect. Dis. 1982, 4:1119-1132.
177. Rubin R. Clinical approach to infection in the compromised host. Infection in the Organ Transplant Recipient 2002, 573-679. Kluwer Academic Press, New York. R. Rubin, L.S. Young (Eds.).
178. Boeckh M., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
179. Boeckh M. Management of cytomegalovirus infections in blood and marrow transplant recipients. Adv. Exp. Med. Biol. 1999, 458:89-109.
180. Valantine H.A., et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001, 72:1647-1652.
181. Valantine H.A. Role of CMV in transplant coronary artery disease and survival after heart transplantation. Transpl. Infect. Dis. 1999, 1(Suppl. 1):25-30.
182. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J. Clin. Virol. 2006, 35:474-477.
183. Griffiths P.D., Clark D.A., Emery V.C. Betaherpesviruses in transplant recipients. J. Antimicrob. Chemother. 2000, 45:29-34.
184. Grundy J.E., et al. The source of cytomegalovirus infection in seropositive renal allograft recipients is frequently the donor kidney. Transplant. Proc. 1987, 19:2126-2128.
185. Grundy J.E., et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988, 16:132-135.
186. Chou S.W. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N. Engl. J. Med. 1986, 314:1418-1423.
187. Chou S.W. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J. Infect. Dis. 1987, 155:1054-1056.
188. Yow M.D., et al. Use of restriction enzymes to investigate the source of a primary cytomegalovirus infection in a pediatric nurse. Pediatrics 1982, 70:713-716.
189. Wilfert C.M., Huang E.S., Stagno S. Restriction endonuclease analysis of cytomegalovirus deoxyribonucleic acid as an epidemiologic tool. Pediatrics 1982, 70:717-721.
190. Klemola E., Kaariainen L. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. BMJ 1965, 2:1099-1102.
191. Andersson J., Stern H. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. BMJ 1966, 1:672.
192. Hassan-Walker A.F., et al. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J. Med. Virol. 1999, 58:182-187.
193. Zaia J.A., et al. Prolonged human cytomegalovirus viremia following bone marrow transplantation. Transplantation 1984, 37:315-317.
194. Zaia J.A. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002, 29:633-638.
195. Spector S.A., et al. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J. Virol. 1999, 73:7027-7030.
196. Emery V.C., et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
197. Grattan M.T., et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561-3566.
198. Melnick J.L., et al. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983, 2:644-647.
199. Nieto F.J., Szklo M., Sorlie P.D. Cytomegalovirus infection and coronary heart disease. Circulation 1999, 100:e139.
200. Nieto F.J., et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996, 94:922-927.
201. Hosenpud J.D. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am. Heart. J. 1999, 138:S469-S472.
202. Koskinen P.K., et al. Cytomegalovirus infection and cardiac allograft vasculopathy. Transplant. Infect. Dis. 1999, 1:115-126.
203. Valantine H.A., et al. Impact on prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post host analysis of a randomized, placebo-controlled study. Circulation 1999, 100:61-66.
204. Zhu J., et al. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J. Am. Coll. Cardiol. 1999, 34:1738-1743.
205. Evans P.C., et al. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000, 69:30-35.
206. Soderberg-Naucler C., Emery V.C. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001, 71:SS24-SS30.
207. Stagno S., et al. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics 1977, 59:669-678.
208. Dahle A.J., et al. Progressive hearing impairment in children with congenital cytomegalovirus infection. J. Speech. Hear. Disord. 1979, 44:220-229.
209. Dahle A., et al. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J. Am. Acad. Audiol. 2000, 11:283-290.
210. Fowler K.B., et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J. Pediatr. 1997, 130:624-630.
211. Fowler K.B., Boppana S.B. Congenital cytomegalovirus (CMV) infection and hearing deficit. J. Clin. Virol. 2006, 35:226-231.
212. Boppana S., Fowler K.B. Persistence in the population: epidemiology and transmission. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis 2007, 795-813. Cambridge University Press, Cambridge. A. Arvin (Ed.).
213. Koskinen P., et al. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall: a possible linkage with enhanced allograft arteriosclerosis. Am. J. Pathol. 1994, 144:41-50.
214. Lemstrom K., et al. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995, 92:2594-2604.
215. Lemstrom K.B., et al. Triple drug immunosuppression significantly reduces immune activation and allograft arteriosclerosis in cytomegalovirus-infected rat aortic allografts and induces early latency of viral infection. Am. J. Pathol. 1994, 144:1334-1347.
216. Li F., et al. Cytomegalovirus infection enhances the neointima formation in rat aortic allografts: effect of major histocompatibility complex class I and class II antigen differences. Transplantation 1998, 65:1298-1304.
217. Zhou Y.F., et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999, 100:1569-1575.
218. Streblow D.N., et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 1999, 99:511-520.
219. Streblow D.N., et al. Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr. Top. Microbiol. Immunol. 2008, 325:397-415.
220. Streblow D.N., et al. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am. J. Transplant. 2008, 8:277-287.
221. Stoddart C.A., et al. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J. Virol. 1994, 68:6243-6253.
222. Noda S., et al. Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. Blood 2006, 107:30-38.
223. Taylor-Wiedeman J., et al. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 1991, 72:2059-2064.
224. Sinclair J., Sissons P. Latent and persistent infections of monocytes and macrophages. Intervirology 1996, 39:293-301.
225. Sacher T., et al. Conditional gene expression systems to study herpesvirus biology in vivo. Med. Microbiol. Immunol. 2008, 197:269-276.
226. Gerna G., et al. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J. Infect. Dis. 1992, 166:1236-1244.
227. Schafer P., et al. Cytomegalovirus cultured from different major leukocyte subpopulations: association with clinical features in CMV immunoglobulin G-positive renal allograft recipients. J. Med. Virol. 2000, 61:488-496.
228. Liapis H., et al. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol. Dial. Transplant. 2003, 18:397-402.
229. Gerna G., et al. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J. Virol. 2000, 74:5629-5638.
230. Kas-Deelen A.M., et al. Uptake of pp 65 in in vitro generated pp65-positive polymorphonuclear cells mediated by phagocytosis and cell fusion?. Intervirology 2001, 44:8-13.
231. The T.H., et al. Cytomegalovirus antigenemia. Rev. Infect. Dis. 1990, 12(S):734-744.
232. van der Bij W., Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin. Infect. Dis. 2001, 33:1.
233. Singh N., et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000, 70:717-722.
234. Nichols W.G., Boeckh M. Recent advances in the therapy and prevention of CMV infections. J. Clin. Virol. 2000, 16:25-40.
235. Boeckh M., et al. Cytomegalovirus pp 65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
236. Nichols W.G., et al. Rising pp 65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001, 97:867-874.
237. Waldman W.J., et al. Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: an in vitro model. J. Infect. Dis. 1995, 171:263-272.
238. Riegler S., et al. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J. Gen. Virol. 2000, 81:393-399.
239. Fish K.N., et al. Cytomegalovirus persistence in macrophages and endothelial cells. Scand. J. Infect. Dis. Suppl. 1995, 99:34-40.
240. Hahn G., Jores R., Mocarski E.S. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3937-3942.
241. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J. Clin. Virol. 2008, 41:180-185.
242. Fish K.N., et al. Human cytomegalovirus persistently infects aortic endothelial cells. J. Virol. 1998, 72:5661-5668.
243. Sinzger C., et al. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J. Gen. Virol. 1995, 76:741-750.
244. Plachter B., Sinzger C., Jahn G. Cell types involved in replication and distribution of human cytomegalovirus. Adv. Virus. Res. 1996, 46:195-261.
245. Sinzger C., et al. Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J. Virol. Method. 1997, 63:103-112.
246. Gerna G., et al. Circulating cytomegalic endothelial cells are associated with high human cytomegalovirus (HCMV) load in AIDS patients with late-stage disseminated HCMV disease. J. Med. Virol. 1998, 55:64-74.
247. Evans P.C., et al. Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J. Hepatol. 1999, 31:913-920.
248. Kas-Deelen A.M., et al. Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection. J. Infect. Dis. 2000, 181:721-724.
249. Maidji E., et al. Transmission of human cytomegalovirus from infected uterine microvascular endothelial cells to differentiating/invasive placental cytotrophoblasts. Virology 2002, 304:53-69.
250. Sinzger C., et al. Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry step dependent on efficient translocation to the nucleus. J. Gen. Virol. 2000, 81:3021-3035.
251. Kahl M., et al. Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J. Virol. 2000, 74:7628-7635.
252. Percivalle E., et al. Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement. J. Clin. Invest. 1993, 92:663-670.
253. Grefte A., et al. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J. Infect. Dis. 1993, 167:270-277.
254. Brune W., et al. A ribonucleotide reductase homolog of cytomegalovirus and endothelial cell tropism. Science 2001, 291:303-305.
255. Fries B.C., et al. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J. Infect. Dis. 1994, 169:769-774.
256. Rasmussen L., et al. Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. J. Infect. Dis. 1997, 175:179-184.
257. Haberland M., Meyer-Konig U., Hufert F.T. Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J. Gen. Virol. 1999, 80:1495-1500.
258. Bale J.F., et al. Intrauterine cytomegalovirus infection and glycoprotein B genotypes. J. Infect. Dis. 2000, 182:933-936.
259. Lurain N.S., et al. Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J. Virol. 1999, 73:10040-10050.
260. Bale J.F., et al. Human cytomegalovirus a sequence and UL144 variability in strains from infected children. J. Med. Virol. 2001, 65:90-96.
261. Rasmussen L., Geissler A., Winters M. Inter- and intragenic variations complicate the molecular epidemiology of human cytomegalovirus. J. Infect. Dis. 2003, 187:809-819.
262. Rasmussen L., et al. The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. J. Virol. 2002, 76:10841-10848.
263. Garrigue I., et al. Variability of UL18, UL40, UL111a and US3 immunomodulatory genes among human cytomegalovirus clinical isolates from renal transplant recipients. J. Clin. Virol. 2007, 40:120-128.
264. Garrigue I., et al. UL40 human cytomegalovirus variability evolution patterns over time in renal transplant recipients. Transplantation 2008, 86:826-835.
265. Hitomi S., et al. Human cytomegalovirus open reading frame UL11 encodes a highly polymorphic protein expressed on the infected cell surface. Arch. Virol. 1997, 142:1407-1427.
266. Pignatelli S., et al. Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identification of a novel subgroup, geographical distribution and evidence of positive selective pressure. J. Gen. Virol. 2003, 84:647-655.
267. Pignatelli S., Dal Monte P., Landini M.P. gpUL73 (gN) genomic variants of human cytomegalovirus isolates are clustered into four distinct genotypes. J. Gen. Virol. 2001, 82:2777-2784.
268. Chou S.W. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J. Infect. Dis. 1989, 160:11-15.
269. Ryckman B.J., et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 2008, 82:60-70.
270. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18153-18158.
271. Hayajneh W.A., et al. The sequence and antiapoptotic functional domains of the human cytomegalovirus UL37 exon 1 immediate early protein are conserved in multiple primary strains. Virology 2001, 279:233-240.
272. Skaletskaya A., et al. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7829-7834.
273. Goldmacher V.S. vMIA, a viral inhibitor of apoptosis targeting mitochondria. Biochimie 2002, 84:177-185.
274. Mocarski E.S. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 2002, 10:332-339.
275. Saederup N., Mocarski E.S. Fatal attraction: cytomegalovirus-encoded chemokine homologs. Curr. Top. Microbiol. Immunol. 2002, 269:235-256.
276. Spencer J.V., et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Virol. 2002, 76:1285-1292.
277. Jenkins C., et al. Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J. Virol. 2008, 82:3736-3750.
278. McCormick A.L. Control of apoptosis by human cytomegalovirus. Curr. Top. Microbiol. Immunol. 2008, 325:281-295.
279. Goldmacher V.S. Cell death suppression by cytomegaloviruses. Apoptosis 2005, 10:251-265.
280. Lockridge K.M., et al. Primate cytomegaloviruses encode and express an IL-10-like protein. Virology 2000, 268:272-280.
281. Arav-Boger R., et al. Human cytomegalovirus-encoded alpha-chemokines exhibit high sequence variability in congenitally infected newborns. J. Infect. Dis. 2006, 193:788-791.
282. Hanson L.K., et al. Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis. J. Virol. 1999, 73:5970-5980.
283. Hanson L.K., et al. Products of US22 genes M140 and M141 confer efficient replication of murine cytomegalovirus in macrophages and spleen. J. Virol. 2001, 75:6292-6302.
284. Bale J.F., O'Neil M.E. Detection of murine cytomegalovirus DNA in circulating leukocytes harvested during acute infection of mice [erratum appears in J Virol 63(9):4120, 1989]. J. Virol. 1989, 63:2667-2673.
285. Collins T.M., Quirk M.R., Jordan M.C. Biphasic viremia and viral gene expression in leukocytes during acute cytomegalovirus infection of mice. J. Virol. 1994, 68:6305-6311.
286. Mitchell B.M., Leung A., Stevens J.G. Murine cytomegalovirus DNA in peripheral blood of latently infected mice is detectable only in monocytes and polymorphonuclear leukocytes. Virology 1996, 223:198-207.
287. Kern E.R. Animal models for cytomegalovirus infection: murine CMV. Handbook of Animal Models of Infection 1999, 927-934. Academic Press, London. O. Zak, M. Sande (Eds.).
288. Reddehase M.J., Podlech J., Grzimek N.K. Mouse models of cytomegalovirus latency: overview. J. Clin. Virol. 2002, 25:S23-S36.
289. Saederup N., et al. Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10881-10886.
290. Saederup N., et al. Murine cytomegalovirus CC chemokine homolog MCK-2 (m131-129) is a determinant of dissemination that increases inflammation at initial sites of infection. J. Virol. 2001, 75:9966-9976.
291. Menard C., et al. Role of murine cytomegalovirus US22 gene family members in replication in macrophages. J. Virol. 2003, 77:5557-5570.
292. Hahn G., et al. The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J. Virol. 2002, 76:9551-9555.
293. Penfold M.E., et al. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9839-9844.
294. Pepose J.S., et al. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985, 92:472-484.
295. Jacobson M.A., et al. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history and response to ganciclovir therapy. QJM 1988, 67:473.
296. Wilcox C.M., et al. Cytomegalovirus colitis in acquired immunodeficiency syndrome: a clinical and endoscopic study. Gastrointest. Endosc. 1998, 48:39-43.
297. Redman T.K., et al. Human cytomegalovirus enhances chemokine production by lipopolysaccharide-stimulated lamina propria macrophages. J. Infect. Dis. 2002, 185:584-590.
298. Compton T., et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol. 2003, 77:4588-4596.
299. Zhu H., et al. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3932-3937.
300. Margulies B.J., Browne H., Gibson W. Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. Virology 1996, 225:111-125.
301. Rosenkilde M.M., et al. Virally encoded 7TM receptors. Oncogene 2001, 20:1582-1593.
302. Beisser P.S., et al. Viral chemokine receptors and chemokines in human cytomegalovirus trafficking and interaction with the immune system, CMV chemokine receptors. Curr. Top. Microbiol. Immunol. 2002, 269:203-234.
303. Beisser P., et al. Chemokines and chemokine receptors encoded by cytomegaloviruses. Human Cytomegalovirus 2008, Springer-Verlag, Berlin. T. Shenk, M.F. Stinski (Eds.).
304. Billstrom Schroeder M., Worthen G.S. Viral regulation of RANTES expression during human cytomegalovirus infection of endothelial cells. J. Virol. 2001, 75:3383-3390.
305. Vomaske J., et al. Differential ligand binding to a human cytomegalovirus chemokine receptor determines cell type-specific motility. PLoS. Pathog. 2009, 5:e1000304.
306. Billstrom Schroeder M., Christensen R., Worthen G.S. Human cytomegalovirus protects endothelial cells from apoptosis induced by growth factor withdrawal. J. Clin. Virol. 2002, 25:S149-S157.
307. Randolph-Habecker J.R., et al. The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine 2002, 19:37-46.
308. Wills M.R., Carmichael A., Sissons J.G. Adaptive cellular immunity of human cytomegalovirus. Cytomegaloviruses: Molecular Biology and Immunology 2006, 341-367. Casiter, Norfolk, UK. M.J. Reddehase (Ed.).
309. Jonjic S., Bubic I., Krmpotic A. Innate immunity to cytomegaloviruses. Cytomegaloviruses: Molecular Biology and Immunology 2006, 285-321. Casiter, Norfolk, UK. M.J. Reddehase (Ed.).
310. Holtappels R., et al. CD8 T-cell-based immunotherapy of cytomegalovirus disease in the mouse model of the immunocompromised bone marrow transplantation recipient. Cytomegaloviruses: Molecular Biology and Immunology 2006, 383-419. Casiter, Norfolk, UK. M.J. Reddehase (Ed.).
311. Steffens H.P., et al. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J. Virol. 1998, 72:1797-1804.
312. Polic B., et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 1998, 188:1047-1054.
313. Krmpotic A., et al. Pathogenesis of murine cytomegalovirus infection. Microbes Infect. 2003, 5:1263-1277.
314. Lucin P., et al. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Virol. 1992, 66:1977-1984.
315. Bantug G.R., et al. CD8+ T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals. J. Immunol. 2008, 181:2111-2123.
316. Jonjic S., et al. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 1994, 179:1713-1717.
317. Cekinovic D., et al. Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J. Virol. 2008, 82:12172-12180.
318. Klenovsek K., et al. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 2007, 110:3472-3479.
319. Reusser P., et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
320. Riddell S.R., et al. Reconstitution of protective CD8+ cytotoxic T lymphocyte responses to human cytomegalovirus in immunodeficient humans by the adoptive transfer of T cell clones. Multidisciplinary Approach to Understanding Cytomegalovirus Disease 1993, 155-164. Elsevier Science, Amsterdam. S. Michelson, S.A. Plotkin (Eds.).
321. Walter E.A., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995, 333:1038-1044.
322. Li C.R., et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
323. Lacey S.F., et al. Characterization of cytotoxic function of CMV-pp 65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002, 74:722-732.
324. Horn B., et al. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution. Pediatr. Infect. Dis. J. 2009, 28:65-67.
325. Cobbold M., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 2005, 202:379-386.
326. Reusser P., et al. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J. Infect. Dis. 1999, 180:247-253.
327. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 1994, 68:8056-8063.
328. Grakoui A., et al. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J. Hepatol. 2006, 45:468-472.
329. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
330. Shin H., et al. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 2007, 204:941-949.
331. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300:339-342.
332. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 1989, 320:1731-1735.
333. Hadaya K., et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am. J. Transplant. 2008, 8:2674-2683.
334. Biron C.A., Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 2001, 13:458-464.
335. Kuijpers T.W., et al. Human NK cells can control CMV infection in the absence of T cells. Blood 2008, 112:914-915.
336. Stern M., et al. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am. J. Transplant. 2008, 8:1312-1317.
337. Zhang S.Y., et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol. Rev. 2008, 226:29-40.
338. Zhang S.Y., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317:1522-1527.
339. Robbins S.H., et al. Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog. 2007, 3:e123.
340. Presti R.M., et al. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J. Exp. Med. 1998, 188:577-588.
341. Rasmussen L., et al. Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J. Infect. Dis. 1994, 170:673-677.
342. Boppana S.B., et al. Virus specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected individuals with HCMV retinitis. J. Infect. Dis. 1995, 171:182-185.
343. Schoppel K., et al. The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J. Infect. Dis. 1997, 175:533-544.
344. Schoppel K., et al. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J. Infect. Dis. 1998, 178:1233-1243.
345. Snydman D.R., et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N. Engl. J. Med. 1987, 317:1049-1054.
346. Snydman D.R., et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind placebo-controlled trial. Ann. Intern. Med. 1993, 119:984-991.
347. Bonaros N.E., et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004, 77:890-897.
348. Bonaros N., et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin. Transplant. 2008, 22:89-97.
349. Hoetzenecker K., et al. Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur. J. Clin. Invest. 2007, 37:978-986.
350. Leroy F., et al. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients. Transplant. Proc. 2006, 38:2324-2326.
351. Raanani P., et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J. Clin. Oncol. 2009, 27:770-781.
352. Winston D.J., et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 1987, 106:12-18.
353. Emanuel D., et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 1988, 109:777-782.
354. Schmidt G.M., et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988, 46:905-907.
355. Boeckh M., et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 2003, 9:543-558.
356. Bowden R.A., et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl. J. Med. 1986, 314:1006-1010.
357. Bowden R.A., et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplantation. J. Infect. Dis. 1991, 164:483-487.
358. Bratcher D.F., et al. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J. Infect. Dis. 1995, 172:944-950.
359. Chatterjee A., et al. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J. Infect. Dis. 2001, 183:1547-1553.
360. Nigro G., et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 2005, 353:1350-1362.
361. Krmpotic A., et al. The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J. Exp. Med. 2001, 190:1285-1296.
362. Jonjic S., et al. Immune evasion of natural killer cells by viruses. Curr. Opin. Immunol. 2008, 20:30-38.
363. Reddehase M.J. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2002, 2:831-844.
364. Reddehase M.J., et al. Murine model of cytomegalovirus latency and reactivation. Curr. Top. Microbiol. Immunol. 2008, 325:315-331.
365. Holtappels R., et al. Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J. Exp. Med. 2004, 199:131-136.
366. Zaia J.A., et al. Infrequent occurrence of natural mutations in the pp 65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates. J. Virol. 2001, 75:2472-2474.
367. Scalzo A.A., Yokoyama W.M. Cmv1 and natural killer cell responses to murine cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 2008, 321:101-122.
368. Voigt V., et al. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13483-13488.
369. Klein M., et al. Strain-specific neutralization of human cytomegalovirus isolates by human sera. J. Virol. 1999, 73:878-886.
370. Britt W.J. Recent advances in the identification of significant human cytomegalovirus-encoded proteins. Transplant. Proc. 1991, 23:64-69.
371. Burkhardt C., et al. The glycoprotein N of human cytomegalovirus induce a strain specific antibody response during natural infection. J. Gen. Virol. 2009, 90:1951-1961.
372. Stagno S., et al. Comparative, serial virologic and serologic studies of symptomatic and subclinical congenital and natally acquired cytomegalovirus infection. J. Infect. Dis. 1975, 132:568-577.
373. Lockridge K.M., et al. Pathogenesis of experimental rhesus cytomegalovirus infection. J. Virol. 1999, 73:9576-9583.
374. Griffith B.P., et al. Inbred guinea pig model of intrauterine infection with cytomegalovirus. Am. J. Pathol. 1986, 122:112-119.
375. Griffith B.P., et al. Cytomegalovirus-induced mononucleosis in guinea pigs. Infect. Immun. 1981, 32:857-863.
376. Griffith B.P., Aquino-de Jesus M.J. Guinea pig model of congenital cytomegalovirus infection. Transplant. Proc. 1991, 23:29-31.
377. Bowen E.F., et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997, 11:889-893.
378. Revello M.G., Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin. Microbiol. Rev. 2002, 15:680-715.
379. Boeckh M., Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 1998, 11:533-554.
380. Pang X.L., et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant. 2009, 9:258-268.
381. Drew W.L. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr. Opin. Infect. Dis. 2007, 20:408-411.
382. Spector S.A., et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J. Clin. Microbiol. 1992, 30:2359-2365.
383. Becroft D.M.O. Prenatal cytomegalovirus infection: epidemiology, pathology, and pathogenesis. Perspective in Pediatric Pathology 1981, 203-241. Masson Press, New York. H.S. Rosenberg, J. Bernstein (Eds.).
384. Stagno S., et al. Congenital and perinatal cytomegaloviral infections. Semin. Perinatol. 1983, 7:31-42.
385. Boppana S.B., et al. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr. Infect. Dis. J. 1992, 11:93-99.
386. Arribas J.R., et al. Cytomegalovirus encephalitis. Ann. Intern. Med. 1996, 125:577-587.
387. Williamson W.D., et al. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 1992, 90:862-866.
388. Ludwig A., Hengel H. Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro. Surveill. 2009, 14:26-32.
389. Ogawa H., et al. Etiology of severe sensorineural hearing loss in children: independent impact of congenital cytomegalovirus infection and GJB2 mutations. J. Infect. Dis. 2007, 195:782-788.
390. Engman M.L., et al. Congenital CMV infection: prevalence in newborns and the impact on hearing deficit. Scand. J. Infect. Dis. 2008, 40:935-942.
391. Barbi M., et al. Multicity Italian study of congenital cytomegalovirus infection. Pediatr. Infect. Dis. J. 2006, 25:156-159.
392. Iwasaki S., et al. Audiological outcome of infants with congenital cytomegalovirus infection in a prospective study. Audiol. Neurootol. 2007, 12:31-36.
393. Grosse S.D., Ross D.S., Dollard S.C. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J. Clin. Virol. 2008, 41:57-62.
394. Griffith B.P., Lucia H.L., Hsiung G.D. Brain and visceral involvement during congenital cytomegalovirus infection of guinea pigs. Pediatr. Res. 1982, 16:455-459.
395. Bia F.J., et al. Cytomegalovirus infections in the guinea pig: experimental models for human disease. Rev. Infect. Dis. 1983, 5:177-195.
396. Bale J.F., Bray P.F., Bell W.E. Neuroradiographic abnormalities in congenital cytomegalovirus infection. Pediatr. Neurol. 1985, 1:42-47.
397. Perlman J.M., Argyle C. Lethal cytomegalovirus infection in preterm infants: clinical, radiological, and neuropathological findings. Ann. Neurol. 1992, 31:64-68.
398. Boppana S.B., et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 1997, 99:409-414.
399. Boesch C., et al. Magnetic resonance imaging of the brain in congenital cytomegalovirus infection. Pediatr. Radiol. 1989, 19:91-93.
400. Barkovich A.J., Lindan C.E. Congenital cytomegalovirus infection of the brain: imaging analysis and embryologic considerations. AJNR Am. J. Neuroradiol. 1994, 15:703-715.
401. Steinlin M.I., et al. Late intrauterine cytomegalovirus infection: clinical and neuroimaging findings. Pediatr. Neurol. 1996, 15:249-253.
402. Picone O., et al. Comparison between ultrasound and magnetic resonance imaging in assessment of fetal cytomegalovirus infection. Prenat. Diagn. 2008, 28:753-758.
403. Baskin H.J., Hedlund G. Neuroimaging of herpesvirus infections in children. Pediatr. Radiol. 2007, 37:949-963.
404. de Vries L.S., et al. The spectrum of cranial ultrasound and magnetic resonance imaging abnormalities in congenital cytomegalovirus infection. Neuropediatrics 2004, 35:113-119.
405. Hayward J.C., et al. Lissencephaly-pachygyria associated with congenital cytomegalovirus infection. J. Child. Neurol. 1991, 6:109-114.
406. Mejaski-Bosnjak V. Congenital CMV infection: a common cause of childhood disability. Dev. Med. Child. Neurol. 2008, 50:403.
407. Suzuki Y., et al. Epilepsy in patients with congenital cytomegalovirus infection. Brain. Dev. 2008, 30:420-424.
408. Sugita K., et al. Magnetic resonance imaging of the brain in congenital rubella virus and cytomegalovirus infections. Neuroradiology 1991, 33:239-242.
409. Tsutsui Y., Kosugi I., Kawasaki H. Neuropathogenesis in cytomegalovirus infection: indication of the mechanisms using mouse models. Rev. Med. Virol. 2005, 15:327-345.
410. Cheeran M.C., et al. Neural precursor cell susceptibility to human cytomegalovirus diverges along glial or neuronal differentiation pathways. J. Neurosci. Res. 2005, 82:839-850.
411. Luo M.H., Schwartz P.H., Fortunato E.A. Neonatal neural progenitor cells and their neuronal and glial cell derivatives are fully permissive for human cytomegalovirus infection. J. Virol. 2008, 82:9994-10007.
412. Tarantal A.F., et al. Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta). J. Infect. Dis. 1998, 177:446-450.
413. Chang W.L., et al. A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques. J. Virol. 2002, 76:9493-9504.
414. van den Pol A.N., Reuter J.D., Santarelli J.G. Enhanced cytomegalovirus infection of developing brain independent of the adaptive immune system. J. Virol. 2002, 76:8842-8854.
415. Zou Y.R., et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
416. Zhu Y., et al. Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat. Neurosci. 2002, 5:719-720.
417. Koontz T., et al. Altered development of the brain after focal herpesvirus infection of the central nervous system. J. Exp. Med. 2008, 205:423-435.
418. Boppana S., Britt W. Cytomegalovirus. Infection and Hearing Impairment 2006, 67-93. John Wiley & Sons, Sussex, UK. V.E. Newton, P.J. Vallely (Eds.).
419. Strauss M. A clinical pathologic study of hearing loss in congenital cytomegalovirus infection. Laryngoscope 1985, 95:951-962.
420. Strauss M. Human cytomegalovirus labyrinthitis. Am. J. Otolaryngol. 1990, 11:292-298.
421. Rarey K.E., Davis L.E. Temporal bone histopathology 14 years after cytomegalic inclusion disease: a case study. Laryngoscope 1993, 103:904-909.
422. Harris J.P., Fan J.T., Keithley E.M. Immunologic responses in experimental cytomegalovirus labyrinthitis. Am. J. Otolaryngol. 1990, 11:304-308.
423. Chen M.C., Harris J.P., Keithley E.M. Immunohistochemical analysis of proliferating cells in a sterile labyrinthitis animal model. Laryngoscope 1998, 108:651-656.
424. Harris J.P., et al. Immunologic and electrophysiological response to cytomegaloviral inner ear infection in the guinea pig. J. Infect. Dis. 1984, 150:523-530.
425. Harris S., et al. Congenital cytomegalovirus infection and sensorineural hearing loss. Ear Hearing. 1984, 5:352-355.
426. Woolf N.K., et al. Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs. J. Infect. Dis. 1989, 160:929-937.
427. Woolf N.K. Guinea pig model of congenital CMV-induced hearing loss: a review. Transplant. Proc. 1991, 23:32-34.
428. Woolf N.K., et al. Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob. Agents Chemother. 1988, 32:865-872.
429. Fukuda S., Keithley E.M., Harris J.P. Experimental cytomegalovirus infection: viremic spread to the inner ear. Am. J. Otolaryngol. 1988, 9:135-141.
430. Fowler K.B., et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 1992, 326:663-667.
431. Demmler G.J. Infectious Diseases Society of America and Centers for Disease Control, Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev. Infect. Dis. 1991, 13:315-329.
432. Monif G.R.G., et al. The correlation of maternal cytomegalovirus infection during varying stages in gestation with neonatal involvement. J. Pediatr. 1972, 80:17-20.
433. Yow M.D., et al. Epidemiologic characteristics of cytomegalovirus infection in mothers and their infants. Am. J. Obstet. Gynecol. 1988, 158:1189-1195.
434. Pass R.F., et al. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J. Clin. Virol. 2006, 35:216-220.
435. Ahlfors K., et al. Secondary maternal cytomegalovirus infection causing symptomatic congenital infection. N. Engl. J. Med. 1981, 305:284.
436. Ahlfors K., Ivarsson S.A., Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden: review of prospective studies available in the literature. Scand. J. Infect. Dis. 1999, 31:443-457.
437. Ahlfors K., Ivarsson S.A., Harris S. Secondary maternal cytomegalovirus infection-a significant cause of congenital disease. Pediatrics 2001, 107:1227-1228.
438. Rahav G., et al. Primary versus nonprimary cytomegalovirus infection during pregnancy. Israel. Emerg. Infect. Dis. 2007, 13:1791-1793.
439. Kaye S., et al. Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The Gambia. J. Infect. Dis. 2008, 197:1307-1314.
440. Zalel Y., et al. Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. Ultrasound Obstet. Gynecol. 2008, 31:417-420.
441. Ahlfors K., et al. Congenital cytomegalovirus infection and disease in Sweden and the relative importance of primary and secondary maternal infections. Scand. J. Infect. Dis. 1984, 16:129-137.
442. Boppana S.B., et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999, 104:55-60.
443. Ross S.A., et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J. Pediatr. 2006, 148:332-336.
444. Ross S.A., Boppana S.B. Congenital cytomegalovirus infection: outcome and diagnosis. Semin. Pediatr. Infect. Dis. 2005, 16:44-49.
445. Griffiths P.D., Baboonian C. A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br. J. Obstet. Gynaecol. 1984, 91:307-315.
446. Yamamoto A.P., et al. Congenital cytomegalovirus infection in preterm and full-term newborn infants from a population with a high seroprevalence rate. Pediatr. Infect. Dis. J. 2001, 20:188-192.
447. Rutter D., Griffiths P., Trompeter R.S. Cytomegalic inclusion disease after recurrent maternal infection. Lancet 1985, 2:1182.
448. Evans T.J., McCollum J.P.K., Valdimarsson H. Congenital cytomegalovirus infection after maternal renal transplantation. Lancet 1975, 1:1359-1360.
449. Laifer S.A., et al. Congenital cytomegalovirus infection in offspring of liver transplant recipients. Clin. Infect. Dis. 1995, 20:52-55.
450. Mussi-Pinhata M.M., et al. Congenital and perinatal cytomegalovirus infection in infants born to mothers infected with human immunodeficiency virus. J. Pediatr. 1998, 132:285-290.
451. Doyle M., Atkins J.T., Rivera-Matos I.R. Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Pediatr. Infect. Dis. J. 1996, 15:1102-1106.
452. Jones M.M., et al. Congenital cytomegalovirus infection and maternal systemic lupus erythematosus: a case report. Arthritis Rheum. 1986, 29:1402-1404.
453. Reynolds D.W., et al. Maternal cytomegalovirus excretion and perinatal infection. N. Engl. J. Med. 1973, 289:1-5.
454. Stagno S., et al. Breast milk and the risk of cytomegalovirus infection. N. Engl. J. Med. 1980, 302:1073-1076.
455. Vochem M., et al. Transmission of cytomegalovirus to preterm infants through breast milk. Pediatr. Infect. Dis. J. 1998, 17:53-58.
456. Stronati M., et al. Breastfeeding and cytomegalovirus infections. J. Chemother. 2007, 19(Suppl. 2):49-51.
457. Takahashi R., et al. Severe postnatal cytomegalovirus infection in a very premature infant. Neonatology 2007, 92:236-239.
458. Yasuda A., et al. Evaluation of cytomegalovirus infections transmitted via breast milk in preterm infants with a real-time polymerase chain reaction assay. Pediatrics 2003, 111:1333-1336.
459. Alford C. Breast milk transmission of cytomegalovirus (CMV) infection. Adv. Exp. Med. Biol. 1991, 310:293-299.
460. Boppana S.B., et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J. Pediatr. 2005, 146:817-823.
461. Lanari M., et al. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics 2006, 117:e76-e83.
462. Sanchez V., et al. Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J. Virol. 1998, 72:3321-3329.
463. Wolf A., Cowden D. Perinatal infections of the central nervous system. J. Neurol. Pathol. Exp. Neurol. 1959, 18:191-243.
464. Naeye R.L. Cytomegalic inclusion disease, the fetal disorder. Am. J. Clin. Pathol. 1967, 47:738-744.
465. Marques Dias M.J., et al. Prenatal cytomegalovirus disease and cerebral microgyria: evidence for perfusion failure, not disturbance of histogenesis, as the major cause of fetal cytomegalovirus encephalopathy. Neuropediatrics 1984, 15:18-24.
466. Arey L.B. Cytomegalic inclusion disease in infancy. Am. J. Dis. Child. 1954, 88:525-526.
467. Troendle Atkins J., et al. Polymerase chain reaction to detect cytomegalovirus DNA in the cerebrospinal fluid of neonates with congenital infection. J. Infect. Dis. 1994, 169:1334-1337.
468. Balcarek K.B., Oh M.K., Pass R.F. Maternal viremia and congenital CMV infection. Multidisciplinary Approach to Understanding Cytomegalovirus Disease 1993, 169-173. Elsevier Science, Amsterdam. S. Michelson, S.A. Plotkin (Eds.).
469. Keithley E.M., Woolf N.K., Harris J.P. Development of morphological and physiological changes in the cochlear induced by cytomegalovirus. Laryngoscope 1989, 99:409-414.
470. Myers E.N., Stool S. Cytomegalic inclusion disease of the inner ear. Laryngoscope 1968, 78:1904-1915.
471. Davis G.L. Cytomegalovirus in the inner ear: case report and electron microscopic study. Ann. Otol. Rhinol. Laryngol. 1969, 78:1179-1188.
472. Boppana S., et al. Late onset and reactivation of chorioretinitis in children with congenital cytomegalovirus infection. Pediatr. Infect. Dis. J. 1994, 13:1139-1142.
473. Anderson K.S., et al. Ocular abnormalities in congenital cytomegalovirus infection. J. Am. Optom. Assoc. 1996, 67:273-278.
474. Mets M.B. Eye manifestations of intrauterine infections. Ophthalmol. Clin. North Am. 2001, 14:521-531.
475. Guyton T.B., et al. New observations in generalized cytomegalic-inclusion disease of the newborn: report of a case with chorioretinitis. N. Engl. J. Med. 1957, 257:803-807.
476. Conboy T.J., et al. Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infection. J. Pediatr. 1987, 111:343-348.
477. Ansari B.M., Davies D.B., Jones M.R. Calcification in liver associated with congenital cytomegalic inclusion disease. J. Pediatr. 1977, 90:661-662.
478. Alix D., Castel Y., Gouedard H. Hepatic calcification in congenital cytomegalic inclusion disease. J. Pediatr. 1978, 92:856.
479. Fetterman G.H., et al. Generalized cytomegalic inclusion disease of the newborn: localization of inclusions in the kidney. Arch. Pathol. 1968, 86:86-94.
480. Reyes C., et al. Cytomegalovirus enteritis in a premature infant. J. Pediatr. Surg. 1997, 32:1545-1547.
481. Pereira L., Maidji E. Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr. Top. Microbiol. Immunol. 2008, 325:383-395.
482. Muhlemann K., Menegus M.A., Miller R.K. Cytomegalovirus in the perfused human term placenta in vitro. Placenta 1995, 16:367-373.
483. Sachdev R., et al. In situ hybridization analysis for cytomegalovirus in chronic villitis. Pediatr. Pathol. 1990, 10:909-917.
484. Benirschke K., Mendoza G.R., Bazeley P.L. Placental and fetal manifestations of cytomegalovirus infection. Virchows Arch. 1974, 16:121-139.
485. Benirschke K., Kaufmann P. Pathology of the Human Placenta 1990, Springer-Verlag, New York.
486. McDonagh S., et al. Patterns of human cytomegalovirus infection in term placentas: a preliminary analysis. J. Clin. Virol. 2006, 35:210-215.
487. Dankner W.M., et al. Polymerase chain reaction for the detection of cytomegalovirus in placentas from congenitally infected infants. Pediatr. Res. 1992, 31:160A.
488. Trincado D.E., et al. Highly sensitive detection and localization of maternally acquired human cytomegalovirus in placental tissue by in situ polymerase chain reaction. J. Infect. Dis. 2005, 192:650-657.
489. La Torre R., et al. Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin. Infect. Dis. 2006, 43:994-1000.
490. Pereira L., et al. Insights into viral transmission at the uterine-placental interface. Trends Microbiol. 2005, 13:164-174.
491. Fisher S., et al. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J. Virol. 2000, 74:6808-6820.
492. Roth I., et al. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J. Exp. Med. 1996, 184:539-548.
493. Blanco O., et al. Human decidual stromal cells express HLA-G: effects of cytokines and decidualization. Hum. Reprod. 2008, 23:144-152.
494. Kuroki K., Maenaka K. Immune modulation of HLA-G dimer in maternal-fetal interface. Eur. J. Immunol. 2007, 37:1727-1729.
495. Hunt J.S., et al. The role of HLA-G in human pregnancy. Reprod. Biol. Endocrinol. 2006, 4(Suppl. 1):S10.
496. Ishitani A., Sageshima N., Hatake K. The involvement of HLA-E and -F in pregnancy. J. Reprod. Immunol. 2006, 69:101-113.
497. McIntire R.H., Hunt J.S. Antigen presenting cells and HLA-G-a review. Placenta 2005, 26(Suppl. A):S104-S109.
498. Schleiss M.R., et al. Preconceptual administration of an alphavirus replicon UL83 (pp 65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 2007, 195:789-798.
499. Weller T.H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. N. Engl. J. Med. 1971, 285:267-274. II.
500. Weller T.H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. N. Engl. J. Med. 1971, 285:203-214. I.
501. Weller T.H., Hanshaw J.B. Virologic and clinical observations on cytomegalic inclusion disease. N. Engl. J. Med. 1962, 266:1233-1244.
502. Malm G., Engman M.L. Congenital cytomegalovirus infections. Semin. Fetal Neonatal Med. 2007, 12:154-159.
503. Hanshaw J.B. Cytomegalovirus infections. Pediatr. Rev. 1983, 4:332.
504. Medearis D.N. Observations concerning human cytomegalovirus infection and disease. Bull. Johns Hopkins Med. J. 1964, 114:181-211.
505. Noyola D.E., et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J. Pediatr. 2001, 138:325-331.
506. Stagno S., et al. Infant pneumonitis associated with cytomegalovirus, chlamydia, pneumocystis, and ureaplasma: a prospective study. Pediatrics 1981, 68:322-329.
507. Stagno S., et al. Defects of tooth structure in congenital cytomegalovirus infection. Pediatrics 1982, 69:646-648.
508. Harris S., et al. Congenital cytomegalovirus infection and sensorineural hearing loss. Ear Hear. 1984, 5:352-355.
509. Hickson L.M.H., Alcock D. Progressive hearing loss in children with congenital cytomegalovirus. J. Paediatr. Child. Health 1991, 27:105-107.
510. Foulon I., et al. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J. Pediatr. 2008, 153:84-88.
511. Barbi M., et al. Neonatal screening for congenital cytomegalovirus infection and hearing loss. J. Clin. Virol. 2006, 35:206-209.
512. Nance W.E., Lim B.G., Dodson K.M. Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. J. Clin. Virol. 2006, 35:221-225.
513. Hicks T., et al. Congenital cytomegalovirus infection and neonatal auditory screening. J. Pediatr. 1993, 123:779-782.
514. Rivera L.B., et al. Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics 2002, 110:762-767.
515. Walter S., et al. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Arch. Dis. Child. Fetal Neonatal Ed. 2008, 93:F280-F285.
516. Williamson W.D., et al. Symptomatic congenital cytomegalovirus: disorders of language, learning and hearing. Am. J. Dis. Child. 1982, 136:902-905.
517. Saigal S., et al. The outcome in children with congenital cytomegalovirus infection: a longitudinal follow-up study. Am. J. Dis. Child. 1982, 136:896-901.
518. Berenberg W., Nankervis G. Long-term follow-up of cytomegalic inclusion disease of infancy. Pediatrics 1970, 37:403.
519. Pass R.F., et al. Outcome of symptomatic congenital CMV infection: results of long-term longitudinal follow-up. Pediatrics 1980, 66:758-762.
520. Ramsay M.E., Miller E., Peckham C.S. Outcome of confirmed symptomatic congenital cytomegalovirus infection. Arch. Dis. Child. 1991, 66:1068-1069.
521. Ivarsson S.A., Lernmark B., Svanberg L. Ten-year clinical, developmental and intellectual follow-up of children with congenital cytomegalovirus infection without neurologic symptoms at one year of age. Pediatrics 1997, 99:800-803.
522. Zagolski O. Vestibular-evoked myogenic potentials and caloric stimulation in infants with congenital cytomegalovirus infection. J. Laryngol. Otol. 2007, 1-6.
523. Kylat R.I., Kelly E.N., Ford-Jones E.L. Clinical findings and adverse outcome in neonates with symptomatic congenital cytomegalovirus (SCCMV) infection. Eur. J. Pediatr. 2006, 165:773-778.
524. Melish M.E., Hanshaw J.B. Congenital cytomegalovirus infection: developmental progress of infants detected by routine screening. Am. J. Dis. Child. 1973, 126:190-194.
525. Kumar M.L., Nankervis G.A., Gold E. Inapparent congenital cytomegalovirus infection: a follow-up study. N. Engl. J. Med. 1973, 288:1370-1377.
526. Reynolds D.W., et al. Inapparent congenital cytomegalovirus infection with elevated cord IgM levels: causal relationship with auditory and mental deficiency. N. Engl. J. Med. 1974, 209:291-296.
527. Williamson W.D., et al. Asymptomatic congenital cytomegalovirus infection. Am. J. Dis. Child. 1990, 144:1365-1368.
528. Kashden J., et al. Intellectual assessment of children with asymptomatic congenital cytomegalovirus infection. J. Dev. Behav. Pediatr. 1998, 19:254-259.
529. Preece P.M., Pearl K.N., Peckham C.S. Congenital cytomegalovirus infection. Arch. Dis. Child. 1984, 59:1120-1126.
530. Pearl K.N., et al. Neurodevelopmental assessment after congenital cytomegalovirus infection. Arch. Dis. Child. 1986, 62:323-326.
531. Conboy T.J., et al. Intellectual development in school-aged children with asymptomatic congenital cytomegalovirus infection. Pediatrics 1986, 77:801-806.
532. Fowler K.B., Stagno S., Pass R.F. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003, 289:1008-1011.
533. Ahlfors K., Ivarsson S.A., Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden: review of prospective studies available in the literature. Scand. J. Infect. Dis. 1999, 31:443-457.
534. Arvin A.M., et al. Vaccine development to prevent cytomegalovirus disease, Report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 2004, 39:233-239.
535. Capretti M.G., et al. Very low birth weight infants born to cytomegalovirus-seropositive mothers fed with their mother's milk: a prospective study. J. Pediatr. 2009, 154:842-848.
536. Neuberger P., et al. Case-control study of symptoms and neonatal outcome of human milk-transmitted cytomegalovirus infection in premature infants. J. Pediatr. 2006, 148:326-331.
537. Hamprecht K., et al. Cytomegalovirus transmission to preterm infants during lactation. J. Clin. Virol. 2008, 41:198-205.
538. Kothari A., Ramachandran V.G., Gupta P. Cytomegalovirus infection in neonates following exchange transfusion. Indian J. Pediatr. 2006, 73:519-521.
539. Nankervis G.A., Bhumbra N.A. Cytomegalovirus infections of the neonate and infant. Adv. Pediatr. Infect. Dis. 1986, 1:61-74.
540. Bhumbra N.A., et al. Evaluation of a prescreening blood donor program for prevention of perinatal transfusion-acquired cytomegalovirus (CMV) infection. J. Perinat. Med. 1988, 16:127-131.
541. Miron D., et al. Incidence and clinical manifestations of breast milk-acquired cytomegalovirus infection in low birth weight infants. J. Perinatol. 2005, 25:299-303.
542. Mussi-Pinhata M.M., et al. Perinatal or early-postnatal cytomegalovirus infection in preterm infants under 34 weeks gestation born to CMV-seropositive mothers within a high-seroprevalence population. J. Pediatr. 2004, 145:685-688.
543. Doctor S., et al. Cytomegalovirus transmission to extremely low-birthweight infants through breast milk. Acta Paediatr. 2005, 94:53-58.
544. Stagno S., et al. Congenital and perinatal cytomegalovirus infections. Semin. Perinatol. 1983, 7:31-42.
545. Yeager A.S., et al. Sequelae of maternally derived cytomegalovirus infections in premature infants. J. Pediatr. 1983, 102:918-922.
546. Paryani S.G., et al. Sequelae of acquired cytomegalovirus infection in premature and sick term infants. J. Pediatr. 1985, 107:451-456.
547. Maschmann J., et al. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin. Infect. Dis. 2001, 33:1998-2003.
548. Yeager A.S. Transfusion-acquired cytomegalovirus infection in newborn infants. Am. J. Dis. Child. 1974, 128:478-483.
549. Ballard R.B., et al. Acquired cytomegalovirus infection in pre-term infants. Am. J. Dis. Child. 1979, 133:482-485.
550. Adler S.P., et al. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr. Infect. Dis. 1983, 2:114-118.
551. Nelson C.T., et al. PCR detection of cytomegalovirus DNA in serum as a diagnostic test for congenital cytomegalovirus infection. J. Clin. Microbiol. 1995, 33:3317-3318.
552. Lazzarotto T., et al. New advances in the diagnosis of congenital cytomegalovirus infection. J. Clin. Virol. 2008, 41:192-197.
553. Demmler G.J., et al. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J. Infect. Dis. 1988, 158:1177-1184.
554. Warren W.P., et al. Comparison of rapid methods of detection of cytomegalovirus in saliva with virus isolation in tissue culture. J. Clin. Microbiol. 1992, 30:786-789.
555. Johansson P.J., et al. Retrospective diagnostics of congenital cytomegalovirus infection performed by polymerase chain reaction in blood stored on filter paper. Scand. J. Infect. Dis. 1997, 29:465-468.
556. Barbi M., et al. Diagnosis of congenital cytomegalovirus infection by detection of viral DNA in dried blood spots. Clin. Diagn. Virol. 1996, 6:27-32.
557. Yamamoto A.Y., et al. Usefulness of blood and urine samples collected on filter paper in detecting cytomegalovirus by the polymerase chain reaction technique. J. Virol. Methods 2001, 97:159-164.
558. Soetens O., et al. Evaluation of different cytomegalovirus (CMV) DNA PCR protocols for analysis of dried blood spots from consecutive cases of neonates with congenital CMV infections. J. Clin. Microbiol. 2008, 46:943-946.
559. Yamagishi Y., et al. CMV DNA detection in dried blood spots for diagnosing congenital CMV infection in Japan. J. Med. Virol. 2006, 78:923-925.
560. Barbi M., Binda S., Caroppo S. Diagnosis of congenital CMV infection via dried blood spots. Rev. Med. Virol. 2006, 16:385-392.
561. Barbi M., et al. Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. J. Clin. Virol. 2000, 17:159-165.
562. Barbi M., et al. Congenital cytomegalovirus infection in a northern Italian region, NEOCMV Group. Eur. J. Epidemiol. 1998, 14:791-796.
563. Boppana S.B., Ross S.A., Novak Z., et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. Jama 2010, 303:1375-1382.
564. Reynolds D.W., Stagno S., Alford C. Laboratory diagnosis of cytomegalovirus infections. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections 1979, 399-439. American Public Health Association, Washington, DC. fifth ed. E. Lennette, N.J. Schmidt (Eds.).
565. Shuster E.A., et al. Monoclonal antibody for rapid laboratory detection of cytomegalovirus infections: characterization and diagnostic application. Mayo Clin. Proc. 1985, 60:577-585.
566. Boppana S.B., et al. Evaluation of a microtiter plate fluorescent antibody assay for rapid detection of human cytomegalovirus infections. J. Clin. Microbiol. 1992, 30:721-723.
567. Stirk P.R., Griffiths P.D. Use of monoclonal antibodies for the diagnosis of cytomegalovirus infection by the detection of early antigen fluorescent foci (DEAFF) in cell culture. J. Med. Virol. 1987, 21:329-337.
568. Balcarek K.B., et al. Neonatal screening for congenital cytomegalovirus infection by detection of virus in saliva. J. Infect. Dis. 1993, 167:1433-1436.
569. Chou S., Merigan T.C. Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N. Engl. J. Med. 1983, 308:921-925.
570. Spector S.A., et al. Detection of human cytomegalovirus in clinical specimens by DNA-DNA hybridization. J. Infect. Dis. 1984, 150:121-126.
571. Lurain N.S., Thompson K.D., Farrand S.K. Rapid detection of cytomegalovirus in clinical specimens by using biotinylated DNA probes and analysis of cross-reactivity with herpes simplex virus. J. Clin. Microbiol. 1986, 24:724-730.
572. Schuster V., et al. Detection of human cytomegalovirus in urine by DNA-DNA and RNA-DNA hybridization. J. Infect. Dis. 1986, 154:309-314.
573. Erice A., et al. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes. J. Clin. Microbiol. 1992, 30:2822-2825.
574. Percivalle E., et al. Comparison of a new Light Diagnostics and the CMV Brite to an in-house developed human cytomegalovirus antigenemia assay. J. Clin. Virol. 2008, 43:13-17.
575. Hernando S., et al. Comparison of cytomegalovirus viral load measure by real-time PCR with pp 65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplant. Proc. 2005, 37:4094-4096.
576. Boeckh M. Rising CMV PP65 antigenemia and DNA levels during preemptive antiviral therapy. Haematologica 2005, 90:439.
577. Sullivan K.M., et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology. Am. Soc. Hematol. Educ. Program 2001, 392-421.
578. Griffiths P.D., Kangro H.O. A user's guide to the indirect solid-phase radioimmunoassay for the detection of cytomegalovirus-specific IgM antibodies. J. Virol. Methods 1984, 8:271-282.
579. Stagno S., et al. Immunoglobulin M antibodies detected by enzyme-linked immunosorbent assay and radioimmunoassay in the diagnosis of cytomegalovirus infections in pregnant women and newborn infants. J. Clin. Microbiol. 1985, 21:930-935.
580. Lazzarotto T., et al. Development of a new cytomegalovirus (CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IGM. J. Clin. Microbiol. 1998, 36:3337-3341.
581. Gentile M., et al. Measurement of the sensitivity of different commercial assays in the diagnosis of CMV infection in pregnancy. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:977-981.
582. Busse C., Strubel A., Schnitzler P. Combination of native and recombinant cytomegalovirus antigens in a new ELISA for detection of CMV-specific antibodies. J. Clin. Virol. 2008, 43:137-141.
583. Lagrou K., et al. Evaluation of the new ARCHITECT CMV IgM, IgG and IgG avidity assays. J. Clin. Microbiol. 2009, 47:1695-1699.
584. Lazzarotto T., et al. Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. Clin. Diagn. Lab. Immunol. 1999, 6:127-129.
585. Lazzarotto T., et al. Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin. Diag. Lab. Immunol. 1997, 4:469-473.
586. Bodeus M., et al. Anticytomegalovirus IgG avidity in pregnancy: a 2-year prospective study. Fetal. Diagn. Ther. 2002, 17:362-366.
587. Bodeus M., Beulne D., Goubau P. Ability of three IgG-avidity assays to exclude recent cytomegalovirus infection. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20:248-252.
588. Kanengisser-Pines B., et al. High cytomegalovirus IgG avidity is a reliable indicator of past infection in patients with positive IgM detected during the first trimester of pregnancy. J. Perinat. Med. 2009, 37:15-18.
589. Revello M.G., Gerna G. Diagnosis and implications of human cytomegalovirus infection in pregnancy. Fetal Matern. Med. Rev. 1999, 11:117-134.
590. Maine G.T., Lazzarotto T., Landini M.P. New developments in the diagnosis of maternal and congenital CMV infection. Expert Rev. Mol. Diagn. 2001, 1:19-29.
591. Revello M.G., et al. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J. Infect. Dis. 1998, 177:1170-1175.
592. Revello M.G., et al. Human cytomegalovirus immediate-early messenger RNA in blood of pregnant women with primary infection and of congenitally infected newborns. J. Infect. Dis. 2001, 184:1078-1081.
593. Donner C., et al. Prenatal diagnosis of 52 pregnancies at risk for congenital cytomegalovirus infection. Obstet. Gynecol. 1993, 82:481-486.
594. Lamy M.E., et al. Prenatal diagnosis of fetal cytomegalovirus infection. Am. J. Obstet. Gynecol. 1992, 166:91-94.
595. Lynch L., et al. Prenatal diagnosis of fetal cytomegalovirus infection. Am. J. Obstet. Gynecol. 1991, 165:714-718.
596. Lipitz S., et al. Prenatal diagnosis of fetal primary cytomegalovirus infection. Obstet. Gynecol. 1997, 89:763-767.
597. Liesnard C.A., Revelard P., Englert Y. Is matching between women and donors feasible to avoid cytomegalovirus infection in artificial insemination with donor semen?. Hum. Reprod. 1998, 13:25-31. discussion 2-4.
598. Lazzarotto T., et al. Prenatal indicators of congenital cytomegalovirus infection. J. Pediatr. 2000, 137:90-95.
599. Lazzarotto T., et al. Congenital cytomegalovirus infection in twin pregnancies: viral load in the amniotic fluid and pregnancy outcome. Pediatrics 2003, 112:153-157.
600. Guerra B., et al. Prenatal diagnosis of symptomatic congential cytomegalovirus infection. Am. J. Obstet. Gynecol. 2000, 183:476-482.
601. Liesnard C., et al. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet. Gynecol. 2000, 95:881-888.
602. Donner C., et al. Accuracy of amniotic fluid testing before 21 weeks' gestation in prenatal diagnosis of congenital cytomegalovirus infection. Prenat. Diagn. 1994, 14:1055-1059.
603. Bodeus M., et al. Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection. Prenat. Diagn. 1999, 19:314-317.
604. Grose C., Meehan T., Weiner C.P. Prenatal diagnosis of congenital cytomegalovirus infection by virus isolation after amniocentesis. Pediatr. Infect. Dis. J. 1992, 11:605-607.
605. Pass R.F. Commentary: Is there a role for prenatal diagnosis of congenital cytomegalovirus infection?. Pediatr. Infect. Dis. J. 1992, 11:608-609.
606. Weiner C.P., Grose C. Prenatal diagnosis of congenital cytomegalovirus infection by virus isolation from amniotic fluid. Am. J. Obstet. Gynecol. 1990, 163:1253-1255.
607. Benoist G., et al. Cytomegalovirus-related fetal brain lesions: comparison between targeted ultrasound examination and magnetic resonance imaging. Ultrasound Obstet. Gynecol. 2008, 32:900-905.
608. Whitley R.J., et al. A pharmacokinetic and pharmacodynamic evaluation of ganciclovir for the treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. J. Infect. Dis. 1997, 175:1080-1086.
609. Kimberlin D.W., et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 2003, 143:16-25.
610. Nigro G., et al. Regression of fetal cerebral abnormalities by primary cytomegalovirus infection following hyperimmunoglobulin therapy. Prenat. Diagn. 2008, 28:512-517.
611. Schleiss M.R. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J. Pediatr. 2007, 151:564-570.
612. Pass R.F., Burke R.L. Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection. Semin. Pediatr. Infect. Dis. 2002, 13:196-204.
613. Pass R.F., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 1999, 180:970-975.
614. Adler S.P., et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis. 1999, 180:843-846.
615. Berencsi K., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis. 2001, 183:1171-1179.
616. Shimamura M., Mach M., Britt W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J. Virol. 2006, 80:4591-4600.
617. Gonczol E., Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin. Biol. Ther. 2001, 1:401-412.
618. Plotkin S.A., et al. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis. 1989, 159:860-865.
619. Adler S.P., et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 1995, 171:26-32.
620. Heineman T.C., et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J. Infect. Dis. 2006, 193:1350-1360.
621. Pass R.F., et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 2009, 360:1191-1199.
622. Reap E.A., et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp 65, IE1, and gB proteins. Clin. Vaccine Immunol. 2007, 14:748-755.
623. Reap E.A., et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 2007, 25:7441-7449.
624. Bernstein D.I., Reap E.A., Katen K., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28:484-493.
625. Wloch M.K., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis. 2008, 197:1634-1642.
626. Hansen S.G., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
627. Cannon M.J., Davis K.F. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 2005, 5:70.
628. Stagno S., Whitley R.J. Herpesvirus infections of pregnancy, Part I: Cytomegalovirus and Epstein-Barr virus infections. N. Engl. J. Med. 1985, 313:1270-1274.
629. Pass R., Stagno S. Cytomegalovirus. Hospital Acquired Infection in the Pediatric Patient 1988, Williams & Wilkins, Baltimore. L. Donowitz (Ed.).
630. Friedman H.M., et al. Acquisition of cytomegalovirus infection among female employees at a pediatric hospital. Pediatr. Infect. Dis. J. 1984, 3:233-235.
631. Murph J.R., et al. The occupational risk of cytomegalovirus infection among day care providers. JAMA 1991, 265:603-608.
632. Bowden R.A. Cytomegalovirus infections in transplant patients: methods of prevention of primary cytomegalovirus. Transplant. Proc. 1991, 23:136-138.
633. Bowden R.A. Transfusion-transmitted cytomegalovirus infection. Hematol. Oncol. Clin. North Am. 1995, 9:155-166.
634. Adler S.P. Transfusion-associated cytomegalovirus infections. Rev. Infect. Dis. 1983, 5:977-993.
635. Lipson S.M., et al. Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am. J. Clin. Pathol. 2001, 116:52-55.
636. Pietersz R.N., van der Meer P.F., Seghatchian M.J. Update on leucocyte depletion of blood components by filtration. Transfus. Sci. 1998, 19:321-328.
637. Xu D., et al. Acquired cytomegalovirus infection and blood transfusion in preterm infants. Acta Paediatr. Jpn. 1995, 37:444-449.
638. Gilbert G.L., et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes, Neonatal Cytomegalovirus Infection Study Group. Lancet 1989, 1:1228-1231.
639. Fisk J.M., Snyder E.L. Universal pre-storage leukoreduction-a defensible use of hospital resources: the Yale-New Haven Hospital experience. Dev. Biol. (Basel) 2005, 120:39-44.
640. Blajchman M.A., et al. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus. Med. Rev. 2001, 15:1-20.
641. Larsson S., et al. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion 1998, 38:271-278.
642. Goelz R., et al. Effects of different CMV-heat-inactivation-methods on growth factors in human breast milk. Pediatr. Res. 2009, 65:458-461.
643. Knorr B., et al. A haemophagocytic lymphohistiocytosis (HLH)-like picture following breastmilk transmitted cytomegalovirus infection in a preterm infant. Scand. J. Infect. Dis. 2007, 39:173-176.
644. Dworsky M., et al. Persistence of cytomegalovirus in human milk after storage. J. Pediatr. 1982, 101:440-443.
645. Maschmann J., et al. Freeze-thawing of breast milk does not prevent cytomegalovirus transmission to a preterm infant. Arch. Dis. Child. Fetal Neonatal Ed. 2006, 91:F288-F290.
646. Hamprecht K., et al. Cytomegalovirus (CMV) inactivation in breast milk: reassessment of pasteurization and freeze-thawing. Pediatr. Res. 2004, 56:529-535.